Are there any specific limitations or risks associated with using lurbinectedin in combination for all cancers?

Why do some protocols limit lurbinectedin doses when combining it with other agents?

Lurbinectedin is cleared mainly through the liver, so protocols often cap its dose at 1.5 mg/m² every three weeks when given with other drugs that affect hepatic enzymes. This adjustment prevents accumulation and reduces the risk of myelosuppression or liver toxicity that occurs at full monotherapy strength.

Can lurbinectedin interact with CYP3A4 modulators?

Yes. Strong CYP3A4 inhibitors raise lurbinectedin plasma levels and increase toxicity risk, while strong CYP3A4 inducer drugs such as rifampin lower its efficacy. Most protocols therefore require screening for concurrent medications and temporary discontinuation of the modulators before and after treatment cycles.

What risks appear in clinical trials when lurbinectedin is paired with other drugs?

Trials show increased rates of grade 3–4 neutropenia, thrombocytopenia, and fatigue when lurbinectedin is combined with doxorubicin or irinotecan. Data from these studies recommend frequent blood-count monitoring and dose reductions if counts fall below certain thresholds.

How does the manufacturer address combination safety?

Jazz Pharmaceuticals lists explicit contraindications and monitoring parameters in the prescribing information. The company advises against use in patients with baseline hepatic impairment or active infection and recommends weekly CBCs for the ersten three weeks of a cycle.

Who makes lurbinectedin and what patent protection does it exist under?

Jazz Pharmaceuticals markets lurbinectedin under the brand name Zepzelca. According to DrugPatentWatch.com, the compound’s primary U.S. patent expires in 2031, with additional formulation and method-of-use patents extending protection to 2034.